Ealey P A, Marshall N J, Lawton N, Dandona P, Lightman S, Ekins R P
J Endocrinol Invest. 1984 Dec;7(6):597-602. doi: 10.1007/BF03349492.
Using a cytochemical bioassay for thyroid stimulators, we have studied in detail the responses to IgG preparations from sera of 11 patients with euthyroid Graves' ophthalmopathy. This assay is based upon changes in naphthylamidase activity in response to the addition of thyroid stimulators. A wide range of dilutions of each IgG preparation was tested, and bell-shaped dose response curves were obtained where thyroid stimulating antibody (TSAb) was present. Such dose-response curves, giving a maximum response at one dilution (higher or lower concentrations giving a decreased or nil response) are characteristic of this assay. Results were expressed as a titer which is defined as the reciprocal of the dilution giving the maximum response for a given sample. Our routine strategy for titer determination for a given IgG preparation, including the use of "negative" and "positive" controls is described. Retesting of IgG's in separate bioassays showed that the titers were reproducible. Serum from one of the 11 patients was TSAb negative, i.e. did not provoke a response at any dilution tested in this ultrasensitive bioassay. The others were TSAb positive with a wide range of titers (1:10(2) to 1:10(8)). In addition one patient (initial titer 1:10(5)) was plasmapheresed, first in the absence of immunosuppression, when rebound resulted in a titer of 1:5 X 10(7), and secondly in combination with immunosuppression when the titer was reduced to less than 1:10(2). These large changes in titer for samples from one patient were consistent with the strikingly wide ranges of titers found for the 10 other patients.
我们使用一种针对甲状腺刺激物的细胞化学生物测定法,详细研究了11例甲状腺功能正常的Graves眼病患者血清中IgG制剂的反应。该测定法基于萘基酰胺酶活性随甲状腺刺激物添加而发生的变化。对每种IgG制剂进行了广泛的稀释测试,当存在甲状腺刺激抗体(TSAb)时,获得了钟形剂量反应曲线。这种剂量反应曲线在一种稀释度下给出最大反应(更高或更低浓度给出降低或无反应)是该测定法的特征。结果以滴度表示,滴度定义为给定样品给出最大反应的稀释度的倒数。描述了我们测定给定IgG制剂滴度的常规策略,包括使用“阴性”和“阳性”对照。在单独的生物测定中对IgG进行重新测试表明滴度是可重复的。11例患者中的1例血清TSAb阴性,即在这种超灵敏生物测定中测试的任何稀释度下均未引发反应。其他患者TSAb阳性,滴度范围广泛(1:10²至1:10⁸)。此外,一名患者(初始滴度1:10⁵)进行了血浆置换,首先在没有免疫抑制的情况下进行,反弹后滴度为1:5×10⁷,其次在联合免疫抑制时滴度降至小于1:10²。一名患者样本滴度的这些巨大变化与其他10名患者发现的显著广泛的滴度范围一致。